MedTrace Logo

Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice

NCT01454024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1031

Last updated 2015-06-12

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of of this study is to evaluate the safety of NovoPen® 3 and/or FlexPen® devices (if available on the market) measured by the number of adverse events and technical complaints in patients with type 1 and type 2 diabetes in routine clinical practice.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Delivery Systems

Interventions

DEVICE

FlexPen®

Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice

DEVICE

NovoPen® 3

Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454024 on ClinicalTrials.gov